...Rebecca Pedersini; Lucia Vassalli; Melanie Claps; Antonella Tulla; Filippo Rodella; Salvatore Grisanti; Vito Amoroso; Elisa Roca; Edda Lucia Simoncini; Alfredo Berruti Objectives: The aim of this study was to investigate efficacy and safety of eribulin in heavily pretreated patients with advanced...

... institution, we have routinely modified FOLFIRINOX by omitting the bolus dose of 5-FU, reducing irinotecan to 75% of the full dose and including routine haematopoietic growth factor support. We report here the results of a retrospective review of the safety and efficacy of mFOLFIRINOX in advanced pancreatic...

...; Subramanian Hariharan; Barbara Capaccetti; Camillo Porta Objectives: Patients with metastatic renal cell carcinoma (mRCC) received sunitinib in a global expanded-access program (EAP). Here, we report the efficacy and safety results for the EAP subpopulation in Italy. Methods: Patients ≥18 years old...

...Cora N. Sternberg; Ian D. Davis; Keith C. Deen; Entisar Sigal; Robert E. Hawkins Objectives: Evaluation of the safety and efficacy of pazopanib, a multikinase angiogenesis inhibitor, in a single-arm, open-label, extension study (VEG107769/NCT00387764) for placebo-treated patients with advanced...

...Erika P. Hamilton; Kimberly L. Blackwell Five randomized phase III trials – AVF2119g, E2100, AVADO, RIBBON-1, and RIBBON-2 – have reported data on the efficacy and safety of bevacizumab, combined with a variety of chemotherapy agents and in various settings, in patients with metastatic breast...

... of bevacizumab to irinotecan improves outcomes regardless of K-ras mutational status. Bevacizumab has a well-established safety profile and the toxicities associated with its use are usually mild in severity and easily manageable. Conclusions: Addition of bevacizumab to irinotecan-containing regimens...

...Marcus Alexander Wörns; Marcus Schuchmann; Christoph Düber; Gerd Otto; Peter Robert Galle; Arndt Weinmann Objective: To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment. Methods: Sunitinib...

... with serious side effects. As adjuvant endocrine therapy is generally administered for long periods of time, the safety and tolerability of agents used in this setting are of particular importance. Due to their superior efficacy over tamoxifen, newer agents, such as the third-generation aromatase inhibitors...

... and chills of mild-to-moderate severity. Cardiotoxicity and infusion-related reactions emerged as the two main safety concerns with the use of Herceptin. Retrospective analysis revealed a higher incidence of heart failure when Herceptin was combined with anthracyclines than that expected with anthracyclines...